Neuralstem Receives Patent Allowance For Compounds; GlaxoSmithKline Buys Own Shares For Cancellation. Print E-mail
By Staff and Wire Reports   
Tuesday, 04 October 2011 19:44
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 4, 2011.

Neuralstem, Inc. (AMEX:CUR) announced it has received patent allowance for U.S. Patent 8,030,492, entitled: "Compositions to Effect Neuronal Growth." The claims covered by the patent include both structure and method claims for inducing neurogenesis and the growth of new neurons, both in-vitro and in-vivo. Neuralstem's first neurogenic patented compound, NSI-189 is currently in a Phase I FDA-approved safety trial in major depressive disorder.

The Phase Ib portion of the trial, in depressed patients, is expected to commence this fall.

---

SciClone Pharmaceuticals Inc.'s (NYSE:GSK) board has authorized the company to repurchase up to $20 million worth of its stock over the next two years.

Like many other companies recently, SciClone said the program reflects confidence in its business. The company, which focuses on treating chronic and life-threatening diseases, has a market capitalization of $202.4 million.

Also Tuesday, the company reaffirmed its full-year guidance, noting that any reduction in shares outstanding could increase fourth quarter and full-year earnings per share.

Second-quarter results from SciClone showed an increase in product sales, though profit for the period declined 64% as operating expenses sharply increased.


Also Tuesday:


AdCare Health Systems, Inc. (NYSE Amex: ADK)
, a leading skilled nursing and assisted living provider, received approximately $6.9 million in gross proceeds during the third quarter from the exercise of approximately 99% of warrants sold in its initial public offering in November 2006 and those sold in a private placement in December 2009.

Antares Pharma, Inc. (NYSE Amex:AIS) announced today that U.S. Patent number 8,021,335 has been granted by United States Patent and Trademark Office (USPTO), covering technology used in the Company’s VIBEX™ platform of needle-assisted jet injection devices.

Bio-Path Holdings, Inc. (OTC BB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that an abstract entitled, “Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)” has been accepted for a poster presentation at the 53rd Annual Meeting of the American Society of Hematology (ASH) to be held December 10 to 13, 2011 in San Diego, California.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company’s anticipated LibiGel new drug application (NDA).

BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the appointment of Peter Garcia to the position of Chief Financial Officer.

Bristol-Myers Squibb Company (NYSE:BMY) will announce financial results for the third quarter of 2011 on Thursday, October 27, 2011.

HWI Global® (OTCBB: HWIC), the Pittsburgh-based clean room design builder, has been awarded the contract to provide specialized design and build construction services for the new Sub-Cellar Level 2 Pharmacy in Mt. Sinai Hospital's Annenberg Building in New York City.

NeoStem, Inc. (NYSE Amex: NBS)
, an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced that the Company and its wholly-owned subsidiary, Progenitor Cell Therapy ("PCT"), will be presenting at three upcoming October conferences: the 2011 World Stem Cell Summit, the AABB Annual Meeting & CTTXPO, and Cell Therapy Bioprocessing.

NeuroMetrix, Inc. (Nasdaq: NURO)
today announced the appointment of Kenneth J. Snow, M.D. as Chief Medical Officer. The appointment was effective October 3, 2011.

Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it will be presenting at the second annual Cancer Immunotherapy: A Long-Awaited Reality Conference on Thursday, October 6, at the New York Academy of Medicine in New York City.

Pacific Biosciences of California, Inc. (NASDAQ: PACB), provider of Single Molecule Real Time (SMRT®) sequencing products, today announced the appointment of Michael J. Glynn as Chief Commercial Officer.

Repligen Corporation (NASDAQ: RGEN) today provided an update on corporate progress in the development of SecreFlo™ for pancreatic imaging, in its bioprocessing business and in the development of its CNS product candidates during Q2 FY2012, ending September 30, 2011.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced plans today to expand its coagulation testing product line in North America beyond physician offices and outpatient clinics with the development of a full line of coagulation analyzers for hospital and reference laboratories.

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the launch of its iPLEX ADME PGx panel developed to genotype polymorphisms in genes associated with drug absorption, distribution, metabolism, and excretion (ADME).

Stevia Corp.(OTCBB: STEV) ("Stevia Corp." or the "Company"), a farm management company focused on the economic development of Stevia, the fastest growing product in the alternative sweetener sector, is pleased to announce and welcome the appointment of Dr. Pablo Erat to the Board of Directors.

Transgenomic, Inc. (OTCBB: TBIO) today announced that Chad Richards, Chief Commercial Officer of Transgenomic, will be presenting at the Craig-Hallum Capital Group’s 2011 Alpha Select Investor Conference on Thursday, October 6th at 9:20 AM Eastern Time at The Roosevelt Hotel in New York City.

Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced development of technical advancements with application to treatment of hearing loss in animals and human through commercialization of a variety of stem cell products to prevent, reverse and restore hearing in cases of hearing loss.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter